Abstract | INTRODUCTION: MATERIAL AND METHODS: Patients in the Malmö Thrombophilia Study ( MATS) were followed post- anticoagulant treatment until the diagnosis of recurrent VTE or the end of the study (mean follow-up 36 months). Among patients with a first episode of unprovoked VTE, we identified 43 patients (9.7%) with recurrent VTE during the follow-up period. Three age- and sex-matched control subjects without recurrent VTE were selected for each case (n = 129). Plasma levels of ApoM were quantified by a sandwich ELISA method. RESULTS: Among all patients, the plasma levels (mean ± SD) of ApoM were not significantly different between patients with recurrent (0.70 ± 0.2) and non-recurrent VTE (0.74 ± 0.2), p = 0.2. However, after stratification of data according to gender, male patients with recurrent VTE showed significantly (p=0.02) lower ApoM levels (0.63 ± 0.2) as compared to those with non-recurrent VTE (0.74 ± 0.2). No significant differences in ApoM levels were found between recurrent (0.8 ± 0.2) and non-recurrent VTE (0.75 ± 0.2) in female patients, p = 0.3. Cox-regression analysis showed that the risk of recurrent VTE was 0.98 (95% CI, 0.96-0.99) for each 0.01 μM increase in ApoM level in male patients (p = 0.042), and this risk remained unchanged after adjusting for inherited thrombophilia and body mass index (p = 0.027). ApoM levels were not associated with the risk of recurrent VTE in female patients. CONCLUSION: Our results show that levels of ApoM in recurrent VTE may differ according to gender and lower levels of ApoM may predict VTE recurrence in male patients.
|
Authors | Ashfaque A Memon, Jan Sundquist, Bengt Zöller, Xiao Wang, Björn Dahlbäck, Peter J Svensson, Kristina Sundquist |
Journal | Thrombosis research
(Thromb Res)
Vol. 133
Issue 3
Pg. 322-6
(Mar 2014)
ISSN: 1879-2472 [Electronic] United States |
PMID | 24359967
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2013 Elsevier Ltd. All rights reserved. |
Chemical References |
- APOM protein, human
- Anticoagulants
- Apolipoproteins
- Apolipoproteins M
- Lipocalins
|
Topics |
- Anticoagulants
(administration & dosage)
- Apolipoproteins
(blood)
- Apolipoproteins M
- Enzyme-Linked Immunosorbent Assay
- Female
- Humans
- Lipocalins
(blood)
- Male
- Middle Aged
- Recurrence
- Risk Factors
- Sex Factors
- Venous Thromboembolism
(blood, pathology)
|